Home Newsfeeds Sidoti & Co. Downgrades McGrath RentCorp to Neutral, Announces $106 Price Target

Sidoti & Co. Downgrades McGrath RentCorp to Neutral, Announces $106 Price Target

Sidoti & Co. analyst Marc Riddick downgrades McGrath RentCorp (NASDAQ:MGRC) from Buy to Neutral and announces $106 price target.

byBenzinga Newsdesk

November 16, 2022

1 minute read

Sidoti & Co. analyst Marc Riddick downgrades McGrath RentCorp (NASDAQ:MGRC) from Buy to Neutral and announces $106 price target.

Apple Likely To Report Lower Q2 Earnings; Here’s A Look At Recent Price Target Changes By The Most Accurate Analysts

By Lisa Levin

May 4, 6:20 AM

Apple Inc. (NASDAQ: AAPL) is expected to report financial results for its second quarter after the closing bell on May 4, 2023.

AAPL

OpenAI Reportedly Negotiating Content Licensing With CNN, Fox, Time Amid New York Times Lawsuit

By Ananya Gairola

January 10, 10:09 PM

OpenAI is negotiating with CNN, Fox Corp., and Time for content licensing amid ongoing copyright infringement allegations and a lawsuit from The New York Times.

MSFT

EXCLUSIVE: PainReform Reaches 50% Enrollment Target For Phase 3 Study For Its Lead Postoperative Pain Drug

By Vandana Singh

April 2, 8:00 AM

PainReform hits a 50% enrollment target in the Phase 3 trial for PRF-110 in bunionectomy. No serious adverse events were reported. Over 200 patients enrolled across 8 U.S. sites. CEO Ilan Hadar is optimistic about PRF-110's potential to revolutionize postoperative pain management.

PRFX

Atara Biotherapeutics Announces Completion Of The ATA188 Phase 2 EMBOLD Study Interim Analysis In Patients With Progressive MS

By Benzinga Newsdesk

July 12, 4:31 PM

Independent Data and Safety Monitoring Committee Recommends Continuing Study Without Sample Size Adjustment IDSMC Did Not Identify Any Safety Concerns Phase 2 Study Target Enrollment Achieved; Final Data

ATRA

Sidoti & Co. Downgrades McGrath RentCorp to Neutral, Announces $106 Price Target

Related Posts

Apple Likely To Report Lower Q2 Earnings; Here’s A Look At Recent Price Target Changes By The Most Accurate Analysts

OpenAI Reportedly Negotiating Content Licensing With CNN, Fox, Time Amid New York Times Lawsuit

EXCLUSIVE: PainReform Reaches 50% Enrollment Target For Phase 3 Study For Its Lead Postoperative Pain Drug

Atara Biotherapeutics Announces Completion Of The ATA188 Phase 2 EMBOLD Study Interim Analysis In Patients With Progressive MS